NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study
M Ueno, Kenji Ikezawa, Yoshito Komatsu, Hiroaki Nagano et autres
Background: Liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) improved survival outcomes of patients with treatment-naïve metastatic pancreatic adenocarcinoma (mPAC) compared with nab-paclitaxel + gemcitabine in the phase III NAPOLI-3 trial. However, no Japanese centre participated in NAPOLI-3. Therefore, this …
jp, fr (code pays fourni par la source)
0 citations
ESMO Gastrointestinal Oncology